Erratum: Bisphosphonate treatment recommendations for oncologists (The Oncologist (2005) 10 (suppl 1) (19-24) DOI: 10.1634/theoncologist.10-90001-19);Bisphosphonate treatment recommendations for oncologists

Oncologist

Volumn 10, Issue SUPPL. 1, 2005, Pages 19-24

  Von Moos, Roger ^a  

^a Ratischen Kantonsspital Chur   (Switzerland)

Author keywords

Bisphosphonates; Ibandronate; Nephrotoxicity; Product information; Product labeling; Renal safety

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CREATININE; IBANDRONIC ACID; N ACETYL BETA GLUCOSAMINIDASE; ZOLEDRONIC ACID;

ABDOMINAL PAIN; BONE PAIN; BREAST CANCER; CONFERENCE PAPER; CREATININE CLEARANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSPEPSIA; ESOPHAGITIS; EUROPEAN UNION; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPOCALCEMIA; KIDNEY FUNCTION; NAUSEA; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 27144474253     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-4-421     Document Type: Erratum

References (30)

1. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
2. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
3. Balla J. The issue of renal safety of zoledronic acid from a nephrologist's point of view. The Oncologist 2005;10:306-308; author reply 311-312.
4. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679.
5. Johnson KB, Gable P, Kaime EM et al. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. J Clin Oncol 2003;22:738.
6. Kloth DD, McDermott RS, Rogatko A et al. Impact of zoledronic acid (Zol) on renal function in patients (pts) with cancer: is constant monitoring necessary? J Clin Oncol 2003;22:738.
7. Stein SH, Davidson R, Tweed A et al. Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer - University of Pennsylvania. J Clin Oncol 2003;22:738.
8. Novartis Pharmaceuticals Corporation. Zometa® (zoledronic acid). US summary of product characteristics. East Hanover, NJ: Novartis Pharmaceuticals Corporation, November 2004.
9. Novartis International AG. Zometa® (zoledronic acid). EU summary of product characteristics. Basel, Switzerland: Novartis International AG, May 2005.
10. Jackson GH. Renal safety of ibandronate. The Oncologist 2005;10(suppl 1):13-17.
11. F. Hoffmann-La Roche Ltd. Bondronat® (ibandronic acid). Summary of product characteristics. Basel, Switzerland: F. Hoffmann-La Roche Ltd., October 2003.
12. Heras P, Karagiannis S, Kritikos K et al. Ibandronate is effective in preventing skeletal events in patients with bone metastases secondary to breast and colorectal cancer. Ann Oncol 2004;15(suppl 3):225.
13. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5:231-235.
14. Ohlmann C, Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer 2003;11:396.
15. Heidenreich A, Ohlmann C, Olbert P et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5):270.
16. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004;22:3587-3592.
17. Neugebauer G, Köhler W, Akinkunmi L et al. Influence of peak ibandronic acid concentrations after 6-mg IV administration with shortened infusion time (15 and 30 minutes) on renal safety in man. J Clin Oncol 2001;20:122A.
18. Body JJ, Bergström B. Ibandronate is well-tolerated by 15-minute infusion in patients with metastatic bone disease from breast cancer and multiple myeloma. Breast Cancer Res Treat 2004;88(suppl 1):135.
19. Diel I, Pecherstorfer M, Body JJ et al. Long-term safety of intravenous ibandronate for up to 4 years in metastatic breast cancer: an open-label trial. Support Care Cancer 2005;13:462.
20. Elomaa I, Kylmala T, Tammela T et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastic [sic] prostatic cancer. Int Urol Nephrol 1992;24:159-166.
21. Jagdev SP, Purohit P, Heatley S et al. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001;12:1433-1438.
22. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995;13:2427-2430.
23. Atula S, Powles T, Paterson A et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 2003;26:661-671.
24. Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-3224.
25. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405.
26. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-1137.
27. Body JJ, Diel IJ, Bell R et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-312.
28. Diel IJ, Body JJ, Lichinitser MR et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704-1712.
29. Body JJ, Lichinitser M, Tjulandin SA et al. Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial. J Clin Oncol 2005;23(suppl 16):12.
30. Bell R, Tripathy D, Bergström B. Tolerability and convenience of oral ibandronate for patients with skeletal metastases. Ann Oncol 2004;15(suppl 3):224.